 |
|
|
| |
Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects
|
| |
| |
IAC 2020 july 6-10
Reported by Jules Levin
Stefaan Rossenu1, Martine Neyens1, Rodica Van Solingen-Ristea1, Bryan Baugh2, Herta Crauwels1
1Janssen Pharmaceutica NV, Research & Development, Beerse, Belgium; 2Janssen Pharmaceutica, Research & Development, Titusville, USA
Reference: 1. Molina JM, et al. Lancet 2011; 378: 238-46; 2. Cohen CJ, et al. Lancet 2011; 378: 229-37; 3. Swindells S, et al. NEJM 2020; 19;382: 1112-23; 4. Orkin C, et al. NEJM 2020 Mar 19;382:1124-35; 5. https://pdf.hres.ca/dpd_pm/00055411.PDF; 6. Verloes R, et al. HIV Med. 2015 Sep;16(8):477-84; 7. Spreen W, et al. J Acquir Immune Defic Syndr. 2014; 67(5): 487-92; 8. Margolis DA, et al. Lancet. 2017;390(10101):1499‐1510; 9.IDWeek 2019™; October 2-6, 2019; Washington, DC
Disclosures and Acknowledgments: All authors are employees of Janssen Research & Development and hold company stocks. Shweta Pitre, ISMPP CMPP provided writing assistance and Robert Achenbach (Janssen Global Services, LLC) provided additional editorial support for the development of this poster.
|
| |
|
|
|
|
|
